Albireo Pharma

Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Here is how Albireo Pharma (ALBO) and GT Biopharma, Inc. (GTBP) have performed compared to their sector so far this year.

Has Albireo Pharma (ALBO) Outpaced Other Medical Stocks This Year?

Albireo promotes international sales of its approved product Bylvay for the treatment of the extremely rare and orphan disease PFIC. Investors do not yet appreciate the full potential of Bylvay, which presents a good entry opportunity for investors.

Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation

BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that The Lancet Gastroenterology & Hepatology published the results of the pivotal PEDFIC 1 trial, which evaluated Bylvay® (odevixibat) for the treatment of progressive familial intrahepatic cholestasis (PFIC). The study met both of its two primary endpoints, demonstrating that Bylvay provided statistically significant improvements in pruritus severity scores and reductions in serum bile acid levels, with rapid, sustained, and consistent results. The full manuscript of the PEDFIC 1 study is available on The Lancet Gastroenterology & Hepatology website.

The Lancet Gastroenterology & Hepatology Publishes Data from Albireo's Landmark PEDFIC 1 Study of Bylvay® (odevixibat) Treatment in PFIC

BOSTON, June 30, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation at the William Blair Biotech Focus Conference July 12-13, 2022. Ron Cooper, President and Chief Executive Officer, will take part in a fireside chat during the conference. Ron and Simon Harford, Chief Financial Officer, will also host meetings during the conference.

Albireo to Present at the William Blair Biotech Focus Conference 2022

BOSTON, June 24, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the presentation of new data at the annual meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) being held in Copenhagen, Denmark. The data provided new analyses of the Phase 3 PEDFIC 1 and PEDFIC 2 trials of Bylvay® (odevixibat), demonstrating that dose escalation can provide greater benefits in relieving patients' pruritus, with similar tolerability, as well as showing that reductions in pruritus are associated with important improvements in sleep and other quality of life measures in children with all types of progressive familial intrahepatic cholestasis (PFIC).

Albireo Presents New Bylvay® (odevixibat) Data at Annual ESPGHAN Congress

BOSTON, June 23, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the presentation of new data in pediatric and adult liver diseases at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 being held in London. The presentations provide new analyses of the Phase 3 PEDFIC 1 and PEDFIC 2 trials of Bylvay® (odevixibat) in progressive familial intrahepatic cholestasis (PFIC), as well as data on pipeline ASBT/NTCP inhibitor compounds, including A2342 in Hepatitis B and D.

Albireo Announces Presentation of New Data in Pediatric and Adult Liver Diseases

– Four abstracts accepted of Phase 3 data from PEDFIC 1 and PEDFIC 2 trials of Bylvay™ (odevixibat)

Albireo to Present New Data at the 54th Annual Meeting of ESPGHAN

BOSTON, June 02, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer will be presenting at the following investor conferences:

Albireo to Participate at Upcoming Investor Conferences

– Six abstracts presented highlighting data on Bylvay TM (odevixibat) and effects on pruritus, serum bile acids, growth and sleep parameters

Albireo Presented Data in Cholestatic Liver Diseases at Digestive Disease Week (DDW) 2022

BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced participation in the H.C. Wainwright Global Life Science Conference May 23-26, 2022. Simon Harford, Chief Financial Officer, will be presenting on Wednesday, May 25, which will be available on-demand on the Albireo Investors page ir.albireopharma.com. Simon and Pamela Stephenson, Chief Commercial Officer, will host meetings with investors.

Albireo to Participate in the H.C. Wainwright Global Investment Conference 2022

Albireo Pharma, Inc. (NASDAQ:ALBO ) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET Company Participants Hans Vitzthum - Managing Director-LifeSci Advisors, LLC Ron Cooper - President & Chief Executive Officer Pamela Stephenson - Chief Commercial Officer Simon Harford - Chief Financial Officer Conference Call Participants Ritu Baral - Cowen Eun Yang - Jefferies Brian Skorney - Baird Andreas Argyrides - Wedbush Securities Ed Arce - H.C. Wainwright Operator Good afternoon, and welcome to the Albireo Pharma First Quarter 2022 Earnings Call.

Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q1 2022 Results - Earnings Call Transcript

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -8.42% and 12.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Albireo Pharma (ALBO) Reports Q1 Loss, Lags Revenue Estimates

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today provided a business update and reported financial results for the quarter ended March 31, 2022.

Albireo Reports Q1 2022 Financial Results and Business Update

Conference call and webcast to be held at 4:30 pm ET Conference call and webcast to be held at 4:30 pm ET

Albireo to Report Q1 2022 Financial Results on May 16

The lead medicine (Bylvay) is already approved to treat an orphan disease known as progressive familial intrahepatic cholestasis. Leveraging a prudent growth strategy, Albireo is aggressively expanding Bylvay's label for other rare conditions.

Albireo: A Speculative Play With Upside

– Phase 3 ASSERT study on track to report topline data by the end of year

Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM (odevixibat) in Alagille Syndrome

Albireo Pharma's (ALBO) CEO Ron Cooper on Q4 2021 Results - Earnings Call Transcript

Albireo Pharma (ALBO) delivered earnings and revenue surprises of 55.12% and 164.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Albireo Pharma (ALBO) Reports Q4 Loss, Tops Revenue Estimates

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2021.

Albireo Reports Q4 and Year-End 2021 Financial Results and Business Update

Albireo Pharma (ALBO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Albireo Pharma (ALBO) This Earnings Season?

BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Michael Gutch, Ph.D., as Chief Financial Officer. Dr. Gutch has extensive experience in the healthcare and pharmaceutical industries and venture capital investment. He served as Executive Director of Corporate Development and Head of Equities at AstraZeneca and was most recently Chief Business Officer and Chief Financial Officer at Entasis Therapeutics, an AstraZeneca spin-off, where he was involved in the company's private financing rounds, its NASDAQ listing in 2018 and in the strategic partnering of its two lead programs.

Noema Pharma Appoints Michael Gutch as Chief Financial Officer

Albireo Pharma (ALBO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Albireo Pharma (ALBO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

BOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the publication of the PICTURE study in Orphanet Journal of Rare Disease . A multinational, retrospective, cross-sectional study, PICTURE evaluated and quantified the impact that progressive familial intrahepatic cholestasis (PFIC) has on caregivers and found a significant caregiver-reported burden on health-related quality of life (HRQoL), impairment of daily activities, reduced sleep, impact on work productivity, career building challenges and relationship strain. The study illustrates for the first time that PFIC levies a substantial burden that extends beyond the individuals with the disease to those caring for them.

Albireo Announces Publication of the PICTURE Study Highlighting the Caregiver Impact of PFIC, a Rare and Devastating Children's Liver Disease

The global launch of Bylvay was more successful than expected and Albireo doubled its net sales guidance for 2021.

Adult Liver Diseases: The R&D Engine Drives Albireo's Long-Term Prospects.

After the approval of Odevixibat in the PFIC, Albireo successfully transforms into a commercial company capable of generating profits.

News for Albireo Pharma Stock (ALBO)